ES2171991T3 - Forma galenica de liberacion prolongada de milnacipran. - Google Patents
Forma galenica de liberacion prolongada de milnacipran.Info
- Publication number
- ES2171991T3 ES2171991T3 ES97938949T ES97938949T ES2171991T3 ES 2171991 T3 ES2171991 T3 ES 2171991T3 ES 97938949 T ES97938949 T ES 97938949T ES 97938949 T ES97938949 T ES 97938949T ES 2171991 T3 ES2171991 T3 ES 2171991T3
- Authority
- ES
- Spain
- Prior art keywords
- hours
- milnacipran
- mum
- dose released
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines Containing Plant Substances (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Polishing Bodies And Polishing Tools (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
EL OBJETO DE LA PRESENTE INVENCION SE REFIERE UNA FORMA GALENICA CON LIBERACION PROLONGADA, DESTINADA A LA ADMINISTRACION POR VIA ORAL DE UNA SOLA DOSIS DIARIA DE ENTRE 60 Y 140 MG DE MILNACIPRANO QUE SE PRESENTA CON UNA FORMA MULTIPARTICULAR, QUE REUNE VARIOS MINIGRANULOS QUE COMPRENDE CADA UNO UNA MINIESFERA ACTIVA QUE COMPRENDE UN NUCLEO DE SACAROSA Y/O DE ALMIDON DE GRANULOMETRIA COMPRENDIDA ENTRE 200 Y 2000 MI M Y QUE CONTIENE ENTRE 150 Y 1000 MI G DE MILNACIPRANO ASI COMO UN AGENTE AGLOMERANTE, ESTANDO CADA MICROGRANULO REVESTIDO POR UNA PELICULA, CON BASE DE AL MENOS UN POLIMERO NO HIDROSOLUBLE PERO PERMEABLE A LOS LIQUIDOS FISIOLOGICOS, DE ESPESOR COMPRENDIDO ENTRE 20 Y 00 MI M, PERMITIENDO DICHA FORMA GALENICA UNA LIBERACION IN VITRO QUE CORRESPONDE AL PERFIL SEGUN ENTRE UN 10 Y UN 55 % DE LA DOSIS LIBERADA EN DOS HORAS, ENTRE UN 40 Y UN 75 % DE LA DOSIS LIBERADA EN 4 HORAS, ENTRE UN 70 Y UN 90 % DE LA DOSIS LIBERADA EN 8 HORAS, ENTRE UN 80 Y UN 100 % DE LA DOSIS LIBERADA EN 12 HORAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9610528A FR2752732B1 (fr) | 1996-08-28 | 1996-08-28 | Forme galenique a liberation prolongee de milnacipran |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2171991T3 true ES2171991T3 (es) | 2002-09-16 |
Family
ID=9495256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97938949T Expired - Lifetime ES2171991T3 (es) | 1996-08-28 | 1997-08-26 | Forma galenica de liberacion prolongada de milnacipran. |
Country Status (14)
Country | Link |
---|---|
US (1) | US6699506B1 (es) |
EP (1) | EP0939626B1 (es) |
JP (2) | JP4549442B2 (es) |
CN (1) | CN1108791C (es) |
AT (1) | ATE213629T1 (es) |
AU (1) | AU727018B2 (es) |
BR (1) | BR9711378A (es) |
CA (1) | CA2264238C (es) |
DE (1) | DE69710757T2 (es) |
DK (1) | DK0939626T3 (es) |
ES (1) | ES2171991T3 (es) |
FR (1) | FR2752732B1 (es) |
PT (1) | PT939626E (es) |
WO (1) | WO1998008495A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19928312A1 (de) * | 1999-06-16 | 2000-12-21 | Schering Ag | Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
WO2003084517A2 (fr) * | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules d’amoxicilline |
CN100553625C (zh) * | 2002-04-09 | 2009-10-28 | 弗拉梅技术公司 | 活性成分微囊的口服混悬液 |
CA2503121A1 (en) * | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20060024366A1 (en) * | 2002-10-25 | 2006-02-02 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
CA2513893A1 (en) * | 2003-01-28 | 2004-08-12 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
ES2310715T3 (es) * | 2003-02-14 | 2009-01-16 | Pierre Fabre Medicament | Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento. |
FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
US8309128B2 (en) | 2005-06-10 | 2012-11-13 | Pierre Fabre Medicament | Stabilized milnacipran formulation |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US20080319083A1 (en) * | 2006-01-27 | 2008-12-25 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
AU2008223091B2 (en) * | 2007-03-02 | 2014-04-24 | Farnam Companies, Inc. | Sustained release pellets comprising wax-like material |
CN101301283B (zh) * | 2007-05-10 | 2011-04-06 | 上海医药工业研究院 | 一种米那普仑的经鼻脑转运组合物 |
EP2110129A1 (en) | 2008-04-18 | 2009-10-21 | Pierre Fabre Medicament | Use of enantiomer (1S, 2R) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients |
CN102202654B (zh) * | 2008-09-04 | 2014-07-30 | 法纳姆公司 | 可咀嚼的缓释制剂 |
US20120065221A1 (en) | 2009-02-26 | 2012-03-15 | Theraquest Biosciences, Inc. | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use |
US20100239681A1 (en) * | 2009-03-20 | 2010-09-23 | Biokey, Inc. | Controlled Release Particulates Containing Water-Insoluble Drug |
FR2943546A1 (fr) * | 2009-03-31 | 2010-10-01 | Nouveaux Produits Pharma Sas | Excipient pharmaceutique fonctionnalise ameliorant la biodisponibilite de substances actives peu solubles, microgranules l'incorporant. |
FR2945449B1 (fr) | 2009-05-15 | 2012-10-05 | Pf Medicament | Procede d'impregnation par co2 supercritique |
US9173845B2 (en) | 2009-08-05 | 2015-11-03 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
WO2011057176A1 (en) | 2009-11-06 | 2011-05-12 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
JP2013517290A (ja) * | 2010-01-14 | 2013-05-16 | ピエール ファーブル メディカモン | レボミルナシプランの安定した剤形 |
WO2011107921A2 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Modified release composition of milnacipran |
WO2011107922A2 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Extended release composition of milnacipran |
JP2013536832A (ja) | 2010-08-30 | 2013-09-26 | ルピン・リミテッド | ミルナシプランの制御放出医薬組成物 |
FR2978350B1 (fr) | 2011-07-28 | 2013-11-08 | Pf Medicament | Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu |
CN102793683B (zh) * | 2012-09-04 | 2013-04-17 | 海南康虹医药科技开发有限公司 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
JP6186139B2 (ja) * | 2013-03-08 | 2017-08-23 | 杏林製薬株式会社 | 口腔内速崩壊性錠剤 |
CN105769823A (zh) * | 2014-12-24 | 2016-07-20 | 上海星泰医药科技有限公司 | 一种左旋盐酸米那普仑缓释胶囊及其制备方法 |
EP3167879A1 (en) * | 2015-11-10 | 2017-05-17 | Evonik Technochemie GmbH | Gastric retention active delivery systems |
CN110711185A (zh) * | 2018-07-11 | 2020-01-21 | 北京万全德众医药生物技术有限公司 | 左旋米那普仑缓释胶囊 |
JP7315383B2 (ja) * | 2019-06-27 | 2023-07-26 | 株式会社Screenホールディングス | インクジェット用水性組成物及び固体製剤 |
CN114569566A (zh) * | 2020-12-02 | 2022-06-03 | 四川科瑞德制药股份有限公司 | 一种盐酸米那普仑制剂的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2508035A1 (fr) * | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
JPS58180481A (ja) | 1982-04-15 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
FR2581059B1 (fr) * | 1985-04-25 | 1988-04-22 | Pf Medicament | Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z) |
FR2581060B1 (fr) * | 1985-04-25 | 1988-07-01 | Pf Medicament | Procede industriel d'obtention du midalcipran |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
FR2640972B1 (es) * | 1988-12-28 | 1991-04-19 | Pf Medicament | |
CA2007181C (en) * | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
FR2677019B1 (fr) | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
EP0640081B1 (en) | 1992-03-31 | 2000-01-12 | Glaxo Group Limited | Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht4 antagonists |
ES2174849T3 (es) * | 1992-06-04 | 2002-11-16 | Smithkline Beecham Corp | Composiciones farmaceuticas con sabor agradable. |
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
-
1996
- 1996-08-28 FR FR9610528A patent/FR2752732B1/fr not_active Expired - Fee Related
-
1997
- 1997-08-26 WO PCT/FR1997/001525 patent/WO1998008495A1/fr active IP Right Grant
- 1997-08-26 PT PT97938949T patent/PT939626E/pt unknown
- 1997-08-26 DK DK97938949T patent/DK0939626T3/da active
- 1997-08-26 CN CN97198442A patent/CN1108791C/zh not_active Expired - Lifetime
- 1997-08-26 EP EP97938949A patent/EP0939626B1/fr not_active Expired - Lifetime
- 1997-08-26 ES ES97938949T patent/ES2171991T3/es not_active Expired - Lifetime
- 1997-08-26 US US09/254,014 patent/US6699506B1/en not_active Expired - Lifetime
- 1997-08-26 AU AU41212/97A patent/AU727018B2/en not_active Expired
- 1997-08-26 DE DE69710757T patent/DE69710757T2/de not_active Expired - Lifetime
- 1997-08-26 BR BR9711378A patent/BR9711378A/pt not_active Application Discontinuation
- 1997-08-26 JP JP51133798A patent/JP4549442B2/ja not_active Expired - Lifetime
- 1997-08-26 CA CA002264238A patent/CA2264238C/fr not_active Expired - Lifetime
- 1997-08-26 AT AT97938949T patent/ATE213629T1/de active
-
2010
- 2010-03-10 JP JP2010053612A patent/JP5431214B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU4121297A (en) | 1998-03-19 |
DE69710757T2 (de) | 2004-11-04 |
ATE213629T1 (de) | 2002-03-15 |
EP0939626B1 (fr) | 2002-02-27 |
JP4549442B2 (ja) | 2010-09-22 |
WO1998008495A1 (fr) | 1998-03-05 |
JP5431214B2 (ja) | 2014-03-05 |
EP0939626A1 (fr) | 1999-09-08 |
US6699506B1 (en) | 2004-03-02 |
JP2000516946A (ja) | 2000-12-19 |
FR2752732A1 (fr) | 1998-03-06 |
CN1108791C (zh) | 2003-05-21 |
PT939626E (pt) | 2002-07-31 |
BR9711378A (pt) | 1999-08-17 |
CA2264238C (fr) | 2009-02-24 |
DK0939626T3 (da) | 2002-05-27 |
FR2752732B1 (fr) | 1998-11-20 |
DE69710757D1 (de) | 2002-04-04 |
CN1232387A (zh) | 1999-10-20 |
CA2264238A1 (fr) | 1998-03-05 |
JP2010163447A (ja) | 2010-07-29 |
AU727018B2 (en) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2171991T3 (es) | Forma galenica de liberacion prolongada de milnacipran. | |
DK1183014T3 (da) | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse | |
CA2306103A1 (en) | Novel once-a-day controlled release sulfonylurea formulation | |
CA2395333A1 (en) | Hydrogel-driven drug dosage form | |
IE831799L (en) | Controlled release naproxen and naproxen sodium tablets. | |
ATE246505T1 (de) | Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix | |
MA24193A1 (fr) | Procedes pour la preparation de conjugue peg-ifn alpha physiologiquement actif, et pour la preparation de compositions pharmaceutiques le contenant et leur utilisation | |
FR2811571B1 (fr) | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif | |
IL211075A (en) | Multi-component preparation with irregular release | |
DE69832816D1 (de) | Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung | |
DE59707812D1 (de) | Opioidantagonisthaltige galenische formulierung | |
FR2683146B1 (fr) | Compositions pharmaceutiques a liberation reglee de la substance medicamenteuse. | |
BR9917012A (pt) | Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral | |
DE60020501D1 (de) | Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe | |
CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
DE60006362D1 (de) | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen | |
RS50298B (sr) | Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina | |
CA2000932A1 (en) | Oral pharmaceutical controlled release multiple unit dosage form | |
CA2417887A1 (en) | Particulate composition of eletriptan | |
IL126892A0 (en) | Pharmaceutical compositions for the sustained release of insoluble active principles | |
ATE367153T1 (de) | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme | |
BR9508202A (pt) | Forma medicinal de carbamazepina com liberação de substáncia atíva retardada | |
EP0761209A3 (en) | Controlled release formulations of ranitidine | |
CO5190691A1 (es) | Formas de administracion oral con la liberacion total controlada de sustancia activa, encontrandose una misma sustancia activa en forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presenta di | |
JO1881B1 (en) | Formula II for multi unit disc calibration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 939626 Country of ref document: ES |